Agenus Inc. (AGEN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.6500 |
| Open | 1.6100 |
| Bid | 1.5200 x 27000 |
| Ask | 1.5700 x 34100 |
| Day's Range | 1.5100 - 1.6200 |
| 52 Week Range | 1.4800 - 6.7900 |
| Volume | |
| Avg. Volume | 4,629,830 |
| Market Cap | 392.951M |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | 85.00 |
| EPS (TTM) | 0.0180 |
| Earnings Date | Mar 14, 2022 - Mar 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.67 |
- Zacks
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of 34.48% and 49.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Agenus Corporate Update and First Quarter 2022 Financial Report
Botensilimab data to be presented and Phase 2 trials to launch.AGEN1571 (ILT2) clinical trials to commence and data presented at AACR.AGEN2373 progressing in the clinic and Gilead milestone payment received. LEXINGTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today provided a corporate update and reported financial results for the fi
- GlobeNewswire
Agenus to Provide Corporate Update and First Quarter 2022 Financial Report
Conference Call on Tuesday, May 10, 2022 at 8:30 a.m. ETLEXINGTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its first quarter 2022 financial results before the market opens on Tuesday, May 10, 2022. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the
